Bruno Brochet

Bordeaux, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 116 publications

Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two‑year Phase IV CLARIFY‑MS Study.

Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two‑year Phase IV CLARIFY‑MS Study.

Journal: Neurology and therapy

Published: June 01, 2026

Episodic memory deficits are associated with social cognitive impairments in multiple sclerosis.

Episodic memory deficits are associated with social cognitive impairments in multiple sclerosis.

Journal: Journal of neurology

Published: April 17, 2026

Interthalamic adhesion alterations in multiple sclerosis: associations with thalamic damage and cognition.

Interthalamic adhesion alterations in multiple sclerosis: associations with thalamic damage and cognition.

Journal: Journal of neurology

Published: April 11, 2026

Summary of Research: Cognition and Employment Status of People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-Year CLARIFY-MS Study.

Summary of Research: Cognition and Employment Status of People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-Year CLARIFY-MS Study.

Journal: Neurology and therapy

Published: March 26, 2026

External validation and improvement of an algorithm that identifies multiple sclerosis relapses in the French national healthcare claims database.

External validation and improvement of an algorithm that identifies multiple sclerosis relapses in the French national healthcare claims database.

Journal: Multiple sclerosis and related disorders

Published: March 05, 2026

Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study.

Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study.

Journal: Neurology and therapy

Published: December 03, 2025

Criteria for the use of plasmapheresesis in optic neuritis: A practice review from French expert centers.

Criteria for the use of plasmapheresesis in optic neuritis: A practice review from French expert centers.

Journal: Revue neurologique

Published: April 22, 2025

Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summary.

Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summary.

Journal: Neurodegenerative disease management

Published: December 16, 2024

Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.

Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.

Journal: Neurology

Published: December 03, 2024

Konectom™ cognitive processing speed test enables reliable remote, unsupervised cognitive assessment in people with multiple sclerosis: Exploring the use of substitution time as a novel digital outcome measure.

Konectom™ cognitive processing speed test enables reliable remote, unsupervised cognitive assessment in people with multiple sclerosis: Exploring the use of substitution time as a novel digital outcome measure.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: June 24, 2024

Sensor-Derived Measures of Motor and Cognitive Functions in People With Multiple Sclerosis Using Unsupervised Smartphone-Based Assessments: Proof-of-Concept Study.

Sensor-Derived Measures of Motor and Cognitive Functions in People With Multiple Sclerosis Using Unsupervised Smartphone-Based Assessments: Proof-of-Concept Study.

Journal: JMIR formative research

Published: May 29, 2024

Vulnerability of Thalamic Nuclei at CSF Interface During the Entire Course of Multiple Sclerosis.

Vulnerability of Thalamic Nuclei at CSF Interface During the Entire Course of Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: April 18, 2024

Showing 1-12 of 116

Last Updated: 09/26/2026